SE448945B - Forfarande for rening och /eller koncentrering av faktor viii-komplexet - Google Patents
Forfarande for rening och /eller koncentrering av faktor viii-komplexetInfo
- Publication number
- SE448945B SE448945B SE7910527A SE7910527A SE448945B SE 448945 B SE448945 B SE 448945B SE 7910527 A SE7910527 A SE 7910527A SE 7910527 A SE7910527 A SE 7910527A SE 448945 B SE448945 B SE 448945B
- Authority
- SE
- Sweden
- Prior art keywords
- factor viii
- solution
- glycine
- precipitate
- complex
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title claims abstract description 17
- 238000004140 cleaning Methods 0.000 title 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 64
- 102000001690 Factor VIII Human genes 0.000 claims abstract description 50
- 108010054218 Factor VIII Proteins 0.000 claims abstract description 50
- 239000004471 Glycine Substances 0.000 claims abstract description 32
- 239000002244 precipitate Substances 0.000 claims abstract description 28
- 239000006228 supernatant Substances 0.000 claims abstract description 25
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 238000000746 purification Methods 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims description 41
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 238000001556 precipitation Methods 0.000 claims description 11
- 239000000337 buffer salt Substances 0.000 claims description 3
- 239000012047 saturated solution Substances 0.000 claims description 3
- 239000007858 starting material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 abstract description 14
- 239000000047 product Substances 0.000 abstract description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 28
- 230000000694 effects Effects 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 210000002381 plasma Anatomy 0.000 description 15
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 238000005119 centrifugation Methods 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 208000009292 Hemophilia A Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 238000005194 fractionation Methods 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 6
- 208000031220 Hemophilia Diseases 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 102100023804 Coagulation factor VII Human genes 0.000 description 2
- 102100026735 Coagulation factor VIII Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010023321 Factor VII Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940012413 factor vii Drugs 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 241001530455 Antigone Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 101001082397 Human adenovirus B serotype 3 Hexon-associated protein Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 101001120093 Pseudoalteromonas phage PM2 Protein P8 Proteins 0.000 description 1
- 101000798993 Pseudomonas putida (strain ATCC 700007 / DSM 6899 / BCRC 17059 / F1) 2-hydroxy-6-oxo-2,4-heptadienoate hydrolase Proteins 0.000 description 1
- 108010081391 Ristocetin Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 229950004257 ristocetin Drugs 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
- Y10S530/831—Cohn fractions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE7910527A SE448945B (sv) | 1979-12-20 | 1979-12-20 | Forfarande for rening och /eller koncentrering av faktor viii-komplexet |
| US06/215,530 US4348315A (en) | 1979-12-20 | 1980-12-11 | Process in purification and concentration of the factor VIII-complex |
| AT80850193T ATE3045T1 (de) | 1979-12-20 | 1980-12-18 | Verfahren zur reinigung und konzentrierung des faktor-viii-komplexes. |
| DE8080850193T DE3062792D1 (en) | 1979-12-20 | 1980-12-18 | A process in purification and concentration of the factor viii-complex |
| EP80850193A EP0032655B2 (de) | 1979-12-20 | 1980-12-18 | Verfahren zur Reinigung und Konzentrierung des Faktor-VIII-Komplexes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE7910527A SE448945B (sv) | 1979-12-20 | 1979-12-20 | Forfarande for rening och /eller koncentrering av faktor viii-komplexet |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE7910527L SE7910527L (sv) | 1981-06-21 |
| SE448945B true SE448945B (sv) | 1987-03-30 |
Family
ID=20339607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7910527A SE448945B (sv) | 1979-12-20 | 1979-12-20 | Forfarande for rening och /eller koncentrering av faktor viii-komplexet |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4348315A (de) |
| EP (1) | EP0032655B2 (de) |
| AT (1) | ATE3045T1 (de) |
| DE (1) | DE3062792D1 (de) |
| SE (1) | SE448945B (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4435318A (en) | 1981-05-22 | 1984-03-06 | Ionics, Incorporated | Electrodialysis preparation of purified AHF concentrate |
| USRE32011E (en) * | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| US4397841A (en) * | 1982-06-28 | 1983-08-09 | Monsanto Company | Production of blood coagulation factor VIII:C |
| DE3481109D1 (de) * | 1983-05-09 | 1990-03-01 | Novo Nordisk As | Antihaemophilie-faktor-viii-konzentrat und dessen herstellungsverfahren. |
| US4965199A (en) * | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US5043428A (en) * | 1984-08-31 | 1991-08-27 | Behringwerke Aktiengesellschaft | Pasteurized, isoagglutinin-free factor VIII preparation and a process for its production |
| US4543210A (en) * | 1984-10-04 | 1985-09-24 | Miles Laboratories, Inc. | Process for producing a high purity antihemophilic factor concentrate |
| DK525384D0 (da) * | 1984-11-05 | 1984-11-05 | Nordisk Insulinlab | Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat |
| US4670394A (en) * | 1984-11-16 | 1987-06-02 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Isolation and culture of adrenal medullary endothelial cells producing blood clotting factor VIII:C |
| US4743680A (en) * | 1985-02-01 | 1988-05-10 | New York University | Method for purifying antihemophilic factor |
| US4952675A (en) * | 1985-02-01 | 1990-08-28 | New York University | Method for purifying antihemophilic factor |
| US4847362A (en) * | 1985-02-01 | 1989-07-11 | New York University | Method for purifying antihemophilic factor |
| US4675385A (en) * | 1985-03-27 | 1987-06-23 | Alpha Therapeutic Corporation | Isolation of human plasma procoagulant protein factor VIII from biological factors |
| DE3926034C3 (de) * | 1989-08-07 | 1996-11-21 | Behringwerke Ag | Verfahren zur Herstellung eines stabilen Faktors VIII |
| AT395597B (de) * | 1991-01-25 | 1993-01-25 | Immuno Ag | Reagens zur bestimmung von faktor viii-aktivitaet |
| US5659017A (en) * | 1995-11-07 | 1997-08-19 | Alpha Therapeutic Corporation | Anion exchange process for the purification of Factor VIII |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3652530A (en) * | 1967-08-28 | 1972-03-28 | American Nat Red Cross | Antihemophilic factor prepared from blood plasma using polyethylene glycol |
| US3631018A (en) * | 1970-05-01 | 1971-12-28 | Baxter Laboratories Inc | Production of stable high-potency human ahf using polyethylene glycol and glycine to fractionate a cryoprecipitate of ahf concentrate |
| US3920625A (en) * | 1973-06-19 | 1975-11-18 | Kabi Ab | Isolation of coagulation factors from biological material using cross linked sulfated, sulfonated carbohydrates |
| CA1101332A (fr) * | 1976-01-30 | 1981-05-19 | Edward Shanbrom | Procedes simplifies pour la preparation de concentres de facteur viii de tres grande purete |
| US4087415A (en) * | 1976-06-09 | 1978-05-02 | William L. Wilson | Antithrombin III |
| US4081432A (en) * | 1977-07-25 | 1978-03-28 | Monsanto Company | Method of separating a Factor IX preparation from plasma using ethylene-maleic anhydride polymers |
| CA1074698A (en) * | 1977-12-19 | 1980-04-01 | Gail A. Rock | Method of collecting anti-hemophilic factor viii from blood and blood plasma |
-
1979
- 1979-12-20 SE SE7910527A patent/SE448945B/sv not_active IP Right Cessation
-
1980
- 1980-12-11 US US06/215,530 patent/US4348315A/en not_active Expired - Lifetime
- 1980-12-18 AT AT80850193T patent/ATE3045T1/de not_active IP Right Cessation
- 1980-12-18 EP EP80850193A patent/EP0032655B2/de not_active Expired
- 1980-12-18 DE DE8080850193T patent/DE3062792D1/de not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| EP0032655A1 (de) | 1981-07-29 |
| ATE3045T1 (de) | 1983-04-15 |
| DE3062792D1 (en) | 1983-05-19 |
| EP0032655B1 (de) | 1983-04-13 |
| US4348315A (en) | 1982-09-07 |
| SE7910527L (sv) | 1981-06-21 |
| EP0032655B2 (de) | 1986-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE448945B (sv) | Forfarande for rening och /eller koncentrering av faktor viii-komplexet | |
| DE69333928T2 (de) | Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes | |
| DE69333724T2 (de) | Hybrider menschlich-schweinlicher faktor viii | |
| DE69735295T2 (de) | Verfahren zur Aufkonzentrierung von Antikörperlösungen | |
| Patek et al. | Hemophilia. II. Some properties of a substance obtained from normal human plasma effective in accelerating the coagulation of hemophilic blood | |
| AT516600B1 (de) | Herstellung von faktor h (fh) und fh-derivaten aus plasma | |
| EP0383234B1 (de) | Pasteurisiertes, gereinigtes von Willebrand-Faktor-Konzentrat und Verfahren zu seiner Herstellung | |
| DE2029455C3 (de) | Verfahren zur Herstellung eines neuen Prothrombinkomplexes | |
| US4203891A (en) | Method of collecting anti-hemophilic factor VIII from blood and blood plasma using heparin or sodium heparin | |
| CN109180776A (zh) | 通过用微细分的二氧化硅处理去除丝氨酸蛋白酶 | |
| FI72653C (fi) | Foerfarande foer framstaellning av ett faktor viii(ahf)-koncentrat. | |
| CN106459140A (zh) | 用于纯化免疫球蛋白的方法 | |
| EP1012191B1 (de) | VERFAHREN ZUR GEWINNUNG VON HOCHREINEM vWF ODER FACTOR VIII/vWF-KOMPLEX | |
| KR101949553B1 (ko) | 혈장 유래 면역글로빈 조성물의 혈전색전성 가능성을 감소시키는 방법 | |
| EP0106269A2 (de) | Verfahren zur Pasteurisierung von antihämophilem Kryopräzipitat (AHK) und danach hergestelltes antihämophiles Kryopräzipitat | |
| SE452250B (sv) | Sett att framstella ett koncentrat av protrombinkomplex | |
| EP0906340B1 (de) | Reinigung von faktor viii-komplex durch immunaffinitätschromatographie | |
| McMeekin | Preparation and properties of serum and plasma proteins. II. Crystallization of a carbohydrate-containing albumin from horse serum | |
| CN103153333A (zh) | 补体因子h的纯化方法 | |
| US3904751A (en) | Process for isolating a fibrin stabilizing factor from human placenta | |
| CA1293941C (en) | Method for preparing antihemophilic factor (ahf) by cold precipitation and for improving solubility of recovered ahf product | |
| EP1405863B1 (de) | Konzentrat eines Faktor VIII:C-haltigen von-Willebrand-Faktors und das dazu gehörige Verfahren | |
| EP0052874A1 (de) | Verfahren zum Erzeugen der Vorgerinnungsaktivität des Faktors VIII | |
| EP3719034A2 (de) | Verfahren zur herstellung einer zusammensetzung mit faktor-8 zur kontrolle der konzentration von von willebrand-faktor (vwf) und von willebrand-faktor | |
| Middleton | Polyelectrolytes and preparation of factor VIIIC |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 7910527-6 Effective date: 19890301 Format of ref document f/p: F |